Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Rheumatology 5, 590 (1 November 2009) | doi:10.1038/nrrheum.2009.205
Pharma news: Adalimumab for AS
Abstract
van der Heijde, D. M. et al. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
